LY03020

DRUG4 trials

Sponsors

Luye Pharma Group Ltd.

Conditions

Alzheimer's Disease PsychosisSchizophrenia

Phase 1

A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects

CompletedNCT06556966

Luye Pharma Group Ltd.Alzheimer's Disease Psychosis, Schizophrenia

Start: 2024-08-19End: 2025-02-13Updated: 2025-05-29

A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020

RecruitingNCT07230652

Luye Pharma Group Ltd.Alzheimer's Disease Psychosis, Schizophrenia

Start: 2025-08-20End: 2026-02-28Target: 40Updated: 2025-11-19

A Food Effect Study of LY03020 in Healthy Subjects

Active, not recruitingNCT07292233

Luye Pharma Group Ltd.Alzheimer's Disease Psychosis, Schizophrenia

Start: 2025-07-30End: 2026-03-30Updated: 2025-12-18

Phase 2

A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia

Not yet recruitingNCT07396870

Luye Pharma Group Ltd.Schizophrenia

Start: 2026-03-31End: 2027-12-31Target: 160Updated: 2026-02-09